MOUD explained
We are delivering MOUD through telehealth, making the gold standard of treatment for opioid use disorder accessible, convenient, and affordable for patients.
Request A DEMO
What is MOUD?
Medications for opioid use disorder (MOUD) is an evidence-based treatment that uses FDA-approved medications in conjunction with counseling and behavioral therapies. The primary aim is to provide a "whole patient" approach to the treatment of opioid use disorder. These medications work by blocking the euphoric effects of opioids, alleviating withdrawal symptoms, and reducing cravings. This multifaceted approach significantly increases the chances of long-term recovery compared to abstinence-based methods.
Free MOUD resource downloads for your patients
Learn about how we provide the best care for our patients with these free downloads
MAT/MOUD blogs and research
After the x-waiver
Learn about the new guidelines practitioners must meet to prescribe buprenorphine for opioid use disorder after the elimination of the X-Waiver program.
READ NOWHow buprenorphine helps the body overcome addiction
Ophelia explores how buprenorphine helps the body overcome opioid addiction, citing research from a variety of government and scientific sources.
READ NOWHow OUD treatment has changed with telemedicine
Understand the challenges of how opioid use disorder was treated in the past and discover how telemedicine has helped change & improve the treatment process.
READ NOWUrine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder
Remote urine drug testing can be successfully adapted to exclusively virtual telehealth settings. Ophelia provides real-time, face-to-face high-quality care adherent to in-person best practices.
READ NOWA virtual-first telehealth treatment model for opioid use disorder
Telehealth for OUD holds promise to rapidly scale high quality accessible care for individuals affected by the opioid crisis.
READ NOWVirtual care for opioid use disorder: An evidence- and value-based approach
The opioid crisis continues to drive increases in opioid-involved mortality and morbidity, and the majority of the estimated 7.6 million individuals with OUD are not receiving treatment.
READ NOW